Ítem
Acceso Abierto

Caracterización de los pacientes con síndrome cardiorrenal tipo I y II en diálisis peritoneal en un centro de diálisis en Bogotá

Mostrar el registro sencillo de la publicación
dc.contributor.advisorMolano Triviño, Alejandra Patricia
dc.contributor.advisorWancjer Meid, Benjamin
dc.creatorPineda Ramirez, Roberto
dc.creatorCastro Iregui, Margarita
dc.creator.degreeEspecialista en Nefrología
dc.date.accessioned2017-03-31T20:48:01Z
dc.date.available2017-03-31T20:48:01Z
dc.date.created2017-03-03
dc.date.issued2017
dc.descriptionIntroducción: La ICC que deteriora la función renal es denominada SCR. La DP se plantea como alternativa que impacta en la función cardíaca, hospitalización, síntomas e incluso en la mortalidad 3-5 . Objetivo: Describir el comportamiento de la función renal residual y la mortalidad en pacientes con síndrome cardiorrenal tipo I Y II en diálisis peritoneal en un centro de diálisis de Bogotá, entre 2013 y 2016. Metodología: Se realizó un estudio de cohorte retrospectivo. Se incluyeron pacientes adultos con SCR I y II que ingresaron al centro para DP desde el 1/08/2013 -1/08/16, con seguimiento a cada paciente hasta el 31/07/16. Se evaluaron variables clínico demográficas y de función renal al inicio y final de la DP, así como mortalidad al finalizar el tratamiento. Los datos fueron extraídos de las historias clínicas del sistema de RTS Renir y Versia. El análisis estadístico se realizó empleando STATA® versión 12.0. La velocidad de cambio de la función renal residual se estimó a partir del coeficiente de regresión de un modelo lineal. La tasa de mortalidad se evaluó mediante el método de Kaplan Meier. Resultados: Se evaluaron 16 pacientes, con edad 71 años ± 10.94, tiempo en diálisis de 10.9 meses y fracción de eyección de 29% ± 12.7. Se obtuvo una tasa de disminución de FRR de 0.75 ml/min/1.73 m2 por c/1,46 meses. La tasa de mortalidad al año fue de 41.61%. La sobrevida a un año fue 68%. La principal causa de muerte fue IAMspa
dc.description.abstractIntroduction: The ICC that impairs renal function is called SCR. PD is an alternative that has an impact on cardiac function, hospitalization, symptoms and even mortality 3-5. Objective: To describe the behavior of residual renal function and mortality in patients with type I and II cardiorenal syndrome in peritoneal dialysis at a Bogotá dialysis center between 2013 and 2016. Methodology: A retrospective cohort study was performed. Adult patients with SCR I and II who entered the center for PD from 08/08/2013 to 08/18/16 were included, with follow-up to each patient until 07/31/16. Clinical demographic and renal function variables were assessed at the beginning and end of PD, as well as mortality at the end of treatment. The data were extracted from the clinical records of the Renir and Versia RTS system. Statistical analysis was performed using STATA® version 12. 0. The rate of change in residual renal function was estimated from the regression coefficient of a linear model. The mortality rate was assessed using the Kaplan Meier method. Results: Sixteen patients, aged 71 years ± 10. 94, 10. 9 months on dialysis and ejection fraction of 29% ± 12. 7 were evaluated. A FRR decrease rate of 0. 75 ml / min / 1. 73 m2 per c / 1. 46 months was obtained. The mortality rate per year was 41. 61%. One-year survival was 68%. The main cause of death was AMI eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_13208
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/13208
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentFacultad de Medicinaspa
dc.publisher.programEspecialización en Nefrologíaspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto completo)spa
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.source.bibliographicCitationGranata A, Clementi A, Virzi GM, Brocca A, de Cal M, Scarfia VR, et al. Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment. European journal of internal medicine. 2016.
dc.source.bibliographicCitationCasado Cerrada J, Perez Calvo JI. [Organ damage and cardiorenal syndrome in acute heart failure]. Medicina clinica. 2014;142 Suppl 1:26-31.
dc.source.bibliographicCitationNunez J, Minana G, Santas E, Bertomeu-Gonzalez V. Cardiorenal Syndrome in Acute Heart Failure: Revisiting Paradigms. Revista espanola de cardiologia (English ed). 2015;68(5):426-35.
dc.source.bibliographicCitationPai P. Cardiorenal syndrome. Hong Kong Journal of Nephrology. 2015;17(2):36-45.
dc.source.bibliographicCitationAdriaan A. Voors et al. 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (2016) 37, 2129 – 2200.
dc.source.bibliographicCitationMontenegro Jesus.Tratado de Dialisis Peritoneal. Elsevier España.2015.
dc.source.bibliographicCitationI-Kuan Wang et al. Permanent Cardiac Pacing in patients with end-stage renal disease undergoing dialysis.Nephrol Dial Transplant; 31:2115-2122.
dc.source.bibliographicCitationRonco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010; 31:703-11.
dc.source.bibliographicCitationFonarow ;ADHERE Scientific Advisory Committee: The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4:S21–S30.
dc.source.bibliographicCitationSchrier RW: Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006; 47: 1–8.
dc.source.bibliographicCitationRenhua Lu. Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure: A Systematic Review. Cardiorenal Med 2015;5: 145–156.
dc.source.bibliographicCitationAdachi Y, Nakagawa Y, Nishio A. Icodextrine preserves residual renal function in patients treated with automated peritoneal dialysis.Perit Dial Int 2006; 26:405.
dc.source.bibliographicCitationUchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32:1669-1677.
dc.source.bibliographicCitationHidaka H, Nakao T.Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis.Nephrology.2003 Aug;8(4):184-91
dc.source.bibliographicCitationMistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group (1994) Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46:496–503
dc.source.bibliographicCitationSmith GL, Shlipak MG, Havranek EP et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005; 111: 1270–1277.
dc.source.bibliographicCitationHanna Fröhlich. Peritoneal ultrafiltration in end-stage chronic heart failure. Clin Kidney J (2015) 8: 219–225
dc.source.bibliographicCitationConstanzo MR, Saltzberg M, O'Sullivan J, et al. Early ultrafiltration in patients with descompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005; 46:2047-51.
dc.source.bibliographicCitationRajapakse NW, Nanayakkara S, Kaye DM. Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment. Pharmacology & therapeutics. 2015;154:1-12.
dc.source.bibliographicCitationScabbia EV, Scabbia L. The Cardio-renal Syndrome (CRS). IJC Metabolic & Endocrine. 2015;9:1-4.
dc.source.bibliographicCitationClementi A, Virzi GM, Brocca A, de Cal M, Pastori S, Clementi M, et al. Advances in the pathogenesis of cardiorenal syndrome type 3. Oxidative medicine and cellular longevity. 2015;2015:148082
dc.source.bibliographicCitationChuasuwan A, Kellum JA. Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Seminars in nephrology. 2012;32(1):31-9.
dc.source.bibliographicCitationClementi A, Virzi GM, Goh CY, Cruz DN, Granata A, Vescovo G, et al. Cardiorenal syndrome type 4: a review. Cardiorenal medicine. 2013;3(1):63-70.
dc.source.bibliographicCitationClementi A, Virzi GM, Brocca A, de Cal M, Vescovo G, Granata A, et al. Cardiorenal syndrome type 4: management. Blood purification. 2013;36(3-4):200-9.
dc.source.bibliographicCitationBrocca A, Virzi GM, Pasqualin C, Pastori S, Marcante S, de Cal M, et al. Cardiorenal syndrome type 5: in vitro cytotoxicity effects on renal tubular cells and inflammatory profile. Analytical cellular pathology (Amsterdam). 2015;2015:469461.
dc.source.bibliographicCitationGiusto Viglino et al. Peritoneal ultrafiltration in congestive heart failure - findings reported from its application in clinical practice: a systematic review. J Nephrol (2015) 28:29–38.
dc.source.bibliographicCitationFelker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364:797-805.
dc.source.bibliographicCitationDomansky M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42:705-708.
dc.source.bibliographicCitationCostanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83.
dc.source.bibliographicCitationSilvio V. Bertoli. Peritoneal ultrafiltration in refractory heart failure: a cohort study Cécile Courivaud, peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Peritoneal Dialysis International2014, Vol. 34, pp. 100–108.
dc.source.bibliographicCitationKarlien Francois. Peritoneal Dialysis for Chronic Congestive Heart Failure. Blood Purif 2015; 40:45–52.
dc.source.bibliographicCitationJessup M et al.: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis andManagement of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977–2016.
dc.source.bibliographicCitationFonarow;ADHERE Scientific Advisory Committee: The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4:S21–S30.
dc.source.bibliographicCitationEknoyan G, Beck GJ, Cheung AK, et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:2010e2019.
dc.source.bibliographicCitationBart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF,Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in decompensated heart 22 failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-2304 [PMID:23131078 DOI: 10.1056/NEJMoa1210357]
dc.source.bibliographicCitationPaniagua R, Amato D, Vonesh E, et al. Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307e1320.
dc.source.bibliographicCitationVan Biesen W, Lameire N, Verbeke F, et al. Residual renal function and volume status in peritoneal dialysis patients: a conflict of interest? J Nephrol 2008; 21:299e304.
dc.source.bibliographicCitationAmir kasory et al.Peritoneal dialysis for chronic cardiorenal syndrome: Lessons learned from ultrafiltration trials, World J Cardiol 2015 July 26; 7(7): 392-396.
dc.source.bibliographicCitationBakris GL, Ritz E, World Kidney Day Steering Committee. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Am Soc Hypertens 2009; 3 : 80e83.
dc.source.bibliographicCitationMoist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556e564.
dc.source.bibliographicCitationTermorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004; 15 (4):1061–1070.
dc.source.bibliographicCitationRonco C, Cicoira M, McCullough PA. Cardiorenal syndrome type pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure.J Am Coll Cardiol 2012;60:10314.
dc.source.bibliographicCitationCruz DN et al: Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013; 182: 117–136.
dc.source.bibliographicCitationMorduchowicz G, Winkler J, Zabludowski JR, Boner G: Effects of residual function in haemodialysis patients. Int Urol Nephrol 26:125-31, 1994.
dc.source.bibliographicCitationGiusto Viglino et al. Peritoneal ultrafiltration in congestive heart failure - findings reported from its application in clinical practice: a systematic review. J Nephrol (2015) 28:29–38
dc.source.bibliographicCitationBorrego F, Selga R, de Álvaro F, Bajo MA et al. Seguimiento de la función renal residual en pacientes en DPCA. La influencia de los aclaramientos peritoneales y de los fármacos. Nefrología. 1993; 13(1):37-46
dc.source.bibliographicCitationWolfson M, Piraino B, Hamburger RJ et al (2002) A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 40:1055–1065
dc.source.bibliographicCitationAltmann P, Butler KC, Flowman D: Residual renal function in hemodialysis patients may protect against hyperaluminemia. Kidney Int 32: 710-3, 1987.
dc.source.bibliographicCitationSmith GL, Shlipak MG, Havranek EP et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005;111: 1270–1277.
dc.source.bibliographicCitationBergman JM, Thorpe KE, Churchill DN; CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol. 2001;12(10):2158–2162.
dc.source.bibliographicCitationHolley JL, Aslam N, Bernardini J, Fried L, Piraino B. The influence of demographic factor and modality on loss of residual renal function in incident peritoneal dialysis patients. Peritoneal Dialysis International 2001 Perit Dial Int. 2001 May-Jun;21(3):302-5.
dc.source.bibliographicCitationFoley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998;9(Suppl.12):S16-S23.
dc.source.bibliographicCitationTian SL, Tian XK, Han QF, Axelsson J, Wang T. Presence of peripheral arterial disease predicts loss of residual renal function in incident CAPD patients Perit Dial Int. 2012 Jan-Feb;32(1):67-72.
dc.source.bibliographicCitationHung AM, Young BS, Chertow GM. The decline in residual renal function in hemodialysis is slow and age dependent. Hemodial Int. 2003 Jan 1;7(1):17-22.
dc.source.bibliographicCitationHunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997 Jun;51(6):1908-19
dc.source.bibliographicCitationCnossen TT, Kooman JP, Konings CJ, Uszko-Lencer NH, Leunissen KM, van der Sande FM. Peritoneal dialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif. 2010; 30(2):146-52.
dc.source.bibliographicCitationCourivaud C, Kazory A, Crépin T, Azar R, Bresson-Vautrin C, Chalopin JM, Ducloux D. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int. 2014 Jan-Feb; 34(1):100-8
dc.source.bibliographicCitationLiao CT, Chen YM, Shiao CC, Hu FC, Huang JW, Kao TW, et al. Rate of decline of residual renal function is associated with all-cause mortality and technique failure in patients on long-term peritoneal dialysis. Nephrol Dial Transplant 2009; 24:2909-14.
dc.source.bibliographicCitationSheppard R, Panyon J, Pohwani AL, Kapoor A, Macgowan G, McNamara D, Mathier M, Johnston JR, Murali S. Intermittent outpatient ultrafiltration for the treatment of severe refractory congestive heart failure. J Card Fail. 2004 Oct; 10(5):380-3.
dc.source.bibliographicCitationKoch M, Haastert B, Kohnle M, Rump LC, Kelm M, Trapp R, Aker S. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail. 2012 May; 14(5):530-9.
dc.source.bibliographicCitationUSRDS. Table H.29. Mortality rates by primary cause of mortality, unadjusted. In: USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the U.S. Bethesda, MD: National Institutes of Health: National Institute of Diabetes Digestive and Kidney Diseases; 2007: H.29.
dc.source.bibliographicCitationAbilash Koratala, Ankur Jain. Ultrafiltration does provide more efficient decongestion compared to conventiona for acute heart failure.International Journal Of Cardiology; December 27, 2016.
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subjectDiálisisspa
dc.subjectPeritonealspa
dc.subjectcardiorenalspa
dc.subject.ddcFarmacología & terapéutica
dc.subject.keyworddialysiseng
dc.subject.keywordPeritonealeng
dc.subject.keywordCardiorenaleng
dc.subject.lembInsuficiencia cardíacaspa
dc.subject.lembTerapia combinadaspa
dc.subject.lembDiuréticos osmóticos::Consecuenciasspa
dc.subject.lembDiálisis renalspa
dc.subject.lembHemodinámicaspa
dc.titleCaracterización de los pacientes con síndrome cardiorrenal tipo I y II en diálisis peritoneal en un centro de diálisis en Bogotáspa
dc.typemasterThesiseng
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTrabajo de gradospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
PinedaRamirez-RobertoCarlos-2017.pdf
Tamaño:
492.57 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Especialización en Nefrología